Oncology Central

Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?


Detecting alterations in blood cell-free DNA (cfDNA) is hoped to be a novel, noninvasive method for diagnosing, prognosing and monitoring cancer patients. Several studies have assessed the usefulness of measuring tumor-specific genetic and epigenetic changes of cfDNA, such as loss of heterozygosity, frequency of mutations, alterations of microsatellites and the methylation of genes in patient blood samples.

To view restricted content, please:

Leave A Comment